[Ten-year changes in clinical characteristics and antiviral treatment patterns of chronic hepatitis B in China: a CR-HepB-based real-world study].

Abstract

Objective: To understand ten-year changes in clinical characteristics and antiviral treatment patterns of chronic hepatitis B in China. Methods: Patients with chronic HBV infection:demographic, virologic, hematologic, blood biochemistry, and antiviral treatment data were extracted from the China Registry of Hepatitis B (CR-HepB) database between 2012 and 2022 for descriptive statistics and change trend analysis. Multiple group comparisons were conducted using the Kruskal Wallis H test, while counting data was compared between groups using χ (2) test. Results: A total of 180 012 patients with chronic HBV infection were included, with a median age of 40 years old, and a male proportion accounting for 60.2%. The HBeAg positive rate was 43.3%. Over time, the median age of new patients each year increased from 39 to 47 years, while the HBeAg positive rate decreased from 51.3% to 32.8%. The initial diagnosis of patients was mainly CHB (71.4%), followed by hepatitis B cirrhosis (11.8%), inactive HBsAg carrier status (10.6%), and chronic HBV carrier status (6.2%). Among the newly registered patients every year from 2012 to 2022, the proportion of hepatitis B cirrhosis remained stable, but after 2019, the proportion of CHB increased and the proportion of other diagnoses decreased. The proportion of patients with cirrhosis increased with age in different age groups, with 3.5%, 19.3%, and 30.4% in the < 40, 40-69, and≥70 age groups, respectively. The proportion of women in patients with cirrhosis also increased with age, from 16.1% in those < 30 years old to 44.3% in those≥80 years old. From 2012 to 2022, the proportion of patients receiving first-line nucleos(t)ide analog antiviral treatment increased year by year, from 51.0% in 2012-2013 to 99.8% in 2022. Conclusion: The CR-HepB registration data reflect the changes in clinical characteristics and antiviral treatment patterns in patients with chronic HBV infection in China over the past ten years and can thus provide a reference to promote hepatitis B diagnosis and treatment practice, as well as scientific research.

• Authors: X Q Xu, H Wang, S Shan, H You, Y M Nan, X Y Xu, Z P Duan, L Wei, J L Hou, H Zhuang, J D Jia, Y Y Kong, China Registry of Hepatitis B (CR-HepB) Group
• Journal: Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology (Zhonghua Gan Zang Bing Za Zhi) Vol. 31 Issue 7 Pg. 698-704 (Jul 20 2023) ISSN: 1007-3418 [Print] China
• PMID: 37580251 (Publication Type: English Abstract, Journal Article)

Chemical References

• Antiviral Agents
• Hepatitis B e Antigens
• Hepatitis B Surface Antigens
• DNA, Viral

Topics

• Humans
• Male
• Female
• Adult
• Aged, 80 and over
• Antiviral Agents (therapeutic use)
• Hepatitis B, Chronic (drug therapy, epidemiology)
• Hepatitis B e Antigens
• Hepatitis B (drug therapy)
• Hepatitis B Surface Antigens
• Hepatitis A
• Liver Cirrhosis (drug therapy)
• China (epidemiology)
• Registries
• Hepatitis B virus (genetics)
• DNA, Viral